Skip to main content
Innate Pharma S.A. (IPHA)
NASDAQ: IPHA · Real-Time Price · USD
1.400
0.00 (0.00%)
Apr 28, 2026, 4:00 PM EDT - Market closed

Innate Pharma Revenue

In the year 2025, Innate Pharma had annual revenue of 9.01M EUR, down -55.25%. Innate Pharma had revenue of 4.14M in the half year ending December 31, 2025, a decrease of -80.67%.

Revenue (ttm)
9.01M EUR
Revenue Growth
-55.25%
P/S Ratio
12.04
Revenue / Employee
51,753 EUR
Employees
174
Market Cap
127.25M USD

Revenue Chart

* This company reports financials in EUR.

History

Fiscal Year End Revenue Change Growth
Dec 31, 20259.01M-11.12M-55.25%
Dec 31, 202420.12M-41.52M-67.36%
Dec 31, 202361.64M3.97M6.88%
Dec 31, 202257.67M32.97M133.47%
Dec 31, 202124.70M-45.07M-64.60%
Dec 31, 2020 Pro Pro Pro
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
Verrica Pharmaceuticals 35.58M
Pyxis Oncology 13.86M
Cibus 3.64M
Cardiff Oncology 593.00K
NeOnc Technologies Holdings 39.99K
Revenue Rankings

IPHA News

More News